13/10/2023 10:44:46 |
0 binh luận
SUMMARY Purpose: The study aimed to initial evaluate the value of interim PET/ CT after 2 cycles of ABVD chemotherapy in Hodgkin lymphoma patients. Material and Methods: The study was carried out retrospective and prospective descriptive study on 56 patients at Tan Trieu K Hospital from March 2020 to June 2022. Patients were examined clinically, paraclinically, had a CT scan or PET/CT film before treatment, then received ABVD chemotherapy, after 2 cycles of being taken and evaluated Interim PET/CT, and continued treatment based on the results. Result of iPET/CT leads to continue or change of regimen continued treatment or change of regimen and follow-up. Results: In a total of 56 patients, male/female ratio: 1/1.6, mean age 30±12.6 (youngest age 7 years old, oldest age 67 years old). 35/56 patients (62.5%) had CT scan and 21/56 patients (37.5%) had background PET/CT scan before treatment. 30.4% had 2 lymph node sites and 28.6 patients had 3 lymph node sites on the body, lymph nodes above the diaphragm 67.9% and lymph nodes both above and below the diaphragm 12,5%. 49 patients had lymph node lesions, short axis size of lymph nodes maximum 27.10±8.3 mm. Lesion to the mediastinum in 15/58 patients (25.8%), spleen in 5 patients. Patients with early stage I-II accounted for 82.1%, advanced stage III-IV accounted for 17.9%. After 2 cycles of ABVD chemotherapy, the response rate on PET/CT was iPET/CT2 (-) 43/56 patients (76.8%, of which Deuville score 1 point 93%) and iPET/CT2 (+) in 13/56 patients (23.3%). The prognostic index of IPS low-risk group (0-2) complete metabolic response was 86.4%. In the high-risk group IPS (4-7) partial metabolic response and complete metabolic response was 54.5% according to Lugano classification. Conclusion: Interim PET/CT has an important role in providing prognostic information in the treatment of ABVD chemotherapy in Hodgkin Lymphoma patients, reducing the toxicity of chemotherapy and determining the next treatment modalities. Keywords: lymphoma Hodgkin, interim PET/CT.